"We are certainly following the 'Make In India' practices. There are many domestic manufacturers that are capable of supplying all of that drugs that are not of the exempt list.
"And therefore no patient in India is going to suffer anymore...Or have to pay any more for the price which they are paying right now because the domestic industry is very much capable of supplying all of those drugs at very good prices," Sinha told reporters on the sidelines of India Digital Summit.
Medicines to treat kidney stones, cancer chemotherapy and radiotherapy, life-threatening heart rhythm disorders, bone diseases, diabetes, Parkinson's disease, antibiotic to treat infections will now attract customs duty.
Besides, interacting with reporters, Sinha said India is now getting big on its technology intervention.
"India is the next big thing in technology. The kind of solutions and mobile app that we are developing are not only helping the people but giving India a leadership role."
"If you don't give (it at 20 per cent price), then whatever kind of market you have in India, it won't sell, so you will have to follow the 80:20 rule," he added.
On the start-up initiative, he said the government wants to cover all such genuine ventures and provide them guidance.
He said the government is on a reform path to change India and a lot of efforts are underway to boost infrastructure.
He said the government has taken a very broad and sweeping transformation for country's infrastructure sector.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
